News
Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress.
Medpace delivered a stunning Q2 2025, with double-digit revenue and net new awards growth. Click here to read why MEDP stock ...
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in ...
Background The evidence on associations between ultra-processed foods (UPF) and lung cancer risk is limited and inconsistent.
Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387 ...
VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...
Restriction to randomised controlled trials may limit applicability to non-randomised ... Figure 1 shows the PRISMA flow diagram of the literature selection in this study. Actual screening numbers ...
BACKGROUND: Whether cannabis is a risk factor for cardiovascular events is unknown. We examined the association between smoking cannabis and cardiovascular events in a cohort of older veterans (66 to ...
Some of the most interesting data are precisely those illustrating the reality of clinical practice of physicians attending ...
Some of the most interesting data are precisely those illustrating the reality of clinical practice of physicians attending ...
Minimalist elegance, stunning displays, and quiet operation are among the top features of Dell's new 14' and 16' laptops. - ...
Studies suggest that some commercially available health tests are inaccurate and unsuitable for public use. Rebecca Coombes , Hristio Boytchev , and Gareth Iacobucci ask if regulation is adequately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results